Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using human monoclonal antibodies, or mAbs, to treat infections. The company was founded by Eric J. Patzer and Vu L. Truong on April 24, 2003 and is headquartered in Los Gatos, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Aridis Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Aridis Pharmaceuticals Inc market cap is $2.9M.
What is the 52-week high for Aridis Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Aridis Pharmaceuticals Inc 52 week high is $0.5395 as of September 20, 2025.
What is the 52-week low for Aridis Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Aridis Pharmaceuticals Inc 52 week low is $0.05 as of September 20, 2025.
What is Aridis Pharmaceuticals Inc stock price today?
Aridis Pharmaceuticals Inc stock price today is $0.0566.
What was Aridis Pharmaceuticals Inc stock price yesterday?
Aridis Pharmaceuticals Inc stock price yesterday was $0.065.
What is the PE ratio of Aridis Pharmaceuticals Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Aridis Pharmaceuticals Inc’s P/E ratio is -0.41.
What is the Price-to-Book ratio of Aridis Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Aridis Pharmaceuticals Inc P/B ratio is -0.2455.
What is Aridis Pharmaceuticals Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Aridis Pharmaceuticals Inc's EBITDA is -15.03.
What is the 50-day moving average of Aridis Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Aridis Pharmaceuticals Inc 50-day moving average is $0.073.